初诊不适合移植老年多发性骨髓瘤患者不同健康状态下化疗方案的疗效及安全性
CSTR:
作者:
作者单位:

(衡水市人民医院血液科,河北 衡水 053000)

作者简介:

通讯作者:

中图分类号:

基金项目:

衡水市2023年度科技计划(第一批)项目(2023014037Z)


Efficacy and safety of chemotherapy regimens in elderly patients with newly diagnosed transplant-ineligible multiple myeloma under different health status
Author:
Affiliation:

(Department of Hematology, Hengshui People′ s Hospital, Hengshui 053000, Hebei Province, China)

Fund Project:

This work was supported by Hengshui2023AnnualScience and TechnologyPlan(First Batch)Project(2023014O37Z).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨初诊不适合移植的老年多发性骨髓瘤(MM)患者不同健康状态下化疗方案的疗效及安全性。方法 回顾性分析2021年6月至2023年6月衡水市人民医院收治的150例初诊不适合移植的老年MM患者的临床资料。采用基于老年综合性评估的衰弱评分法,评估患者的基线健康状态,并根据评估结果将患者分为衰弱组(n=54)、一般健康组(n=50)及健康组(n=46)。比较三组患者化疗效果、化疗相关不良反应。采用SPSS 27.0统计软件进行数据分析。绘制Kaplan-Meier曲线分析三组患者1年累积生存率。结果 衰弱组患者中达到完全缓解(CR)及以上疗效、非常好的部分缓解(VGPR)及以上疗效、部分缓解(PR)及以上疗效者占比均低于健康组,达到PR及以上疗效者占比低于一般健康组(P<0.05)。且健康组中采用达雷妥尤单抗/硼替佐米/美法仑/泼尼松(D-VMP)治疗达到VGPR及以上疗效者占比高于二联及三联治疗者,差异有统计学意义(P<0.05)。衰弱组患者肝功能异常、≥3级血液学不良反应、血栓事件发生率均高于健康组及一般健康组,周围神经病变发生率高于健康组(P<0.05)。且健康组中,采用D-VMP治疗者周围神经病变发生率高于二联治疗者。一般健康组中,采用D-VMP治疗者≥3级血液学不良反应、血栓事件、感染以及周围神经病变发生率高于二联治疗者。衰弱组中,采用D-VMP治疗者肝功能异常、≥3级血液学不良反应、血栓事件及感染发生率高于二联治疗者,差异均有统计学意义(P<0.05)。健康组患者1年累积生存率为74.80%,一般健康组为58.3%,衰弱组为52.10%,三组累积生存率比较,差异有统计学意义(log-rankχ2=8.661,P=0.013)。结论 基于衰弱评分的基线健康状态是影响老年初诊不适合移植MM患者化疗效果及预后的重要因素。健康老年MM患者经D-VMP治疗的疗效最优,一般健康及衰弱患者应用D-VMP治疗的疗效不显著。值得注意的是,D-VMP治疗过程中不良反应发生率较高,临床应加强对患者不良反应的监测,必要时调整或更改治疗方案。

    Abstract:

    Objective To evaluate the efficacy and safety of chemotherapy regimens in elderly patients with newly diagnosed transplant-ineligible multiple myeloma (MM) under different health status. Methods A retrospective analysis was conducted of the clinical data of 150 elderly patients with newly diagnosed transplant-ineligible MM in Hengshui People′ s Hospital from June 2021 to June 2023. The patients′ baseline health status was assessed using a frailty scoring method based on comprehensive geriatric assessment. According to the assessment results, the patients were divided into a frail group (n=54), a generally healthy group (n=50) and a healthy group (n=46). The chemotherapy effect and chemotherapy-related adverse reactions were compared among the three groups. Data analysis was performed by SPSS 27.0. Kaplan-Meier curves were plotted to analyze the 1-year cumulative survival rate of the three groups. Results The proportions of patients achieving efficacy complete response (CR) or better, very good partial response (VGPR) or better, and partial response (PR) or better in the frail group were all lower than those in the healthy group, and the proportion of patients achieving PR or better was lower than that in generally healthy group (P<0.05). In the healthy group, the proportion of patients achieving VGPR or better with daratumumab/bortezomib/melphalan/prednisone (D-VMP) was higher than that with doublet or triplet regiments (P<0.05). The incidence of liver function abnormalities, ≥ grade 3 hematological adverse reactions, and thrombotic events in the frail group was higher than that in both the healthy group and the generally healthy group, and the incidence of peripheral neuropathy was higher than that in the healthy group (P<0.05). In the healthy group, the incidence rate of peripheral neuropathy with D-VMP treatment was higher than that with doublet regimens. In the generally healthy group, the incidence rate of ≥ grade 3 hematological adverse reactions, thrombotic events, infections, and peripheral neuropathy with D-VMP treatment was higher than that with doublet regimens. In the frail group, the incidence of liver function abnormalities, ≥ grade 3 hematological adverse reactions, thrombotic events, and infections with D-VMP treatment was higher than that with doublet regimens, and all differences were statistically significant (P<0.05). The 1-year cumulative survival rate was 74.80% in the healthy group, 58.3% in the generally healthy group, and 52.10% in the frail group. There was a statistically significant difference in the cumulative survival rate among the three groups (log-rank χ2=8.661, P=0.013). Conclusion The baseline health status based on frailty score is a critical factor affecting the efficacy and prognosis of chemotherapy in elderly patients with newly diagnosed transplant-ineligible MM. D-VMP treatment yields the best efficacy in healthy elderly MM patients, while its efficacy is not significant in generally healthy and frail patients. Notably, the incidence of adverse reactions during D-VMP treatment is higher, necessitating enhanced clinical monitoring of adverse reactions and potential adjustments or modifications in the treatment regimens when necessary.

    参考文献
    相似文献
    引证文献
引用本文

刘培培,张永晓,刑晶晶.初诊不适合移植老年多发性骨髓瘤患者不同健康状态下化疗方案的疗效及安全性[J].中华老年多器官疾病杂志,2026,25(2):135-140
DOI:10.11915/j. issn.1671-5403.2026.02.029

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2025-02-17
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-02-03
  • 出版日期:
文章二维码